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In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of
the most common inflammatory skin diseases worldwide. However, most of these markers are not only psoriasis-
specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene
expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen
planus, contact eczema, and healthy controls). We identified a cluster of IL-17/tumor necrosis factor-a (TNFa)-
associated genes specifically expressed in psoriasis, among which IL-36g was the most outstanding marker. In
subsequent immunohistological analyses, IL-36g was confirmed to be expressed in psoriasis lesions only. IL-36g
peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after
anti-TNFa-treatment. Furthermore, IL-36g immunohistochemistry was found to be a helpful marker in the
histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These
features highlight IL-36g as a valuable biomarker in psoriasis patients, both for diagnostic purposes and
measurement of disease activity during the clinical course. Furthermore, IL-36g might also provide a future drug
target, because of its potential amplifier role in TNFa- and IL-17 pathways in psoriatic skin inflammation.
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INTRODUCTION
Psoriasis vulgaris (Pso), atopic dermatitis (AD), contact eczema
(CE), and lichen planus (LP) all represent common chronic
inflammatory skin diseases where differential diagnosis based
on clinical features and histology can, in some cases, be
difficult. They are associated with variable concomitant ill-
nesses, low health-related quality of life, and collectively have
a considerable economic burden. Mechanistically, these
entities share different genetic and environmental influences
and are orchestrated by a complex network of common and
specific pro-inflammatory mediators that result in the
expressed clinical phenotypes.
Despite their at times similar clinical appearance to ery-
throsquamous plaques, these skin diseases are driven by
strictly different pathomechanisms, thus offering the possibility
for accurate molecular diagnostics. Psoriasis is thought to be
mainly mediated by T helper (Th) type 1/Th17 cytokines
with a central role of tumor necrosis factor-a (TNF-a), whereas
Th2 cytokines are supposed to have a key role in AD (
Guttman-Yassky et al., 2011; Bieber et al., 2012; Perera et al.,
2012). CE lesions are characterized by Th1-mediated CCL
chemokines, whereas LP is most probably driven by a type I
IFN-mediated inflammation (Pedersen et al., 2007; Wenzel
et al., 2008).
As the exact diagnosis of these diseases is a matter of great
importance for patient-specific therapy, several earlier studies
investigated the value of a number of genes and proteins as
potential specific biomarkers (Bieber et al., 2012; Villanova
et al., 2013). Unfortunately, most of these markers, like the
S100 proteins A7, A8, and A9, are common inflammatory
mediators that are highly expressed in psoriasis (Semprini
et al., 1999; Liu et al., 2007) but also in other inflammatory
skin diseases (Glaser et al., 2009; Kerkhoff et al., 2012).
Here we present data of 150 patients with different
inflammatory skin disorders, demonstrating that IL-36g, an
IL-1F cytokine formerly known as IL-1F9, is specifically
expressed in psoriasis skin lesions and closely associated with
disease activity.
RESULTS
Chronic skin diseases are characterized by the expression of
common pro-inflammatory mediators
Initially, an unsupervised hierarchical gene cluster analysis to
visualize the average linkage of all genes specifically
expressed within the different subsets was performed
(Figure 1a). This identified a set of genes that were commonly
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upregulated in all inflammatory skin diseases (‘‘general
inflammation’’) but not in healthy controls (HCs). Importantly,
this gene-set encompassed nearly all of the top-regulated
genes found in the different skin diseases as given in
Table 1, including the S100 proteins A7, A8, A9, keratins
KRT6 and KRT16, the IFN-regulated IFI27, as well as LCE3 and
DEFB4. The mean expression rates of all significantly regu-
lated genes are provided in Supplementary Table 1 online.
Downregulation of genes involved in regulation and
differentiation of inflammatory skin diseases
Inversely to the pro-inflammatory factors commonly expressed
in all inflammatory skin diseases, we found a set of jointly
downregulated genes, reflecting the diminished immune
regulation and differentiation in skin inflammation. These
genes included WIF1, which has a role in tissue differentia-
tion, LTBP4, which is involved in the regulation of TGF beta
bioavailability, the keratins KRT8 and KRT18, and the anti-
inflammatory IL-37, which is a natural suppressor of innate
inflammatory and immune responses (Nold et al., 2010).
Expression of specific gene clusters in different inflammatory
skin diseases
As depicted in Figure 1a, the unsupervised cluster analysis
highlighted the expression of specific gene clusters in different
skin diseases. Genes associated with CCL chemokines (CCL17
and CCL19) and those reflecting a type II IFN-driven inflamma-
tion (IFITM1, IFI30, and SOCS1) were found in AD and LP, as
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Figure 1. Gene expression analyses of lesional skin (psoriasis and other inflammatory skin diseases). (a) Unsupervised hierarchical gene cluster analysis including
all 189 specifically expressed genes in one of the diseases as identified by Significance Analysis for Microarrays (SAM) (42-fold expressed, Po0.01). (b) Top 10
upregulated genes in psoriasis when compared with HC, CE, LP, and AD, identified via SAM. (c) Volcano plot including all 1,539 genes of the original data set.
Higher y-axis values ( log10 transformed P-values) correspond to a higher significance level of differentially expressed genes in a two-group comparison
(psoriasis versus other skin diseases). The x-axis indicates the difference in gene expression between the two groups. Gene expression values were log2 transformed
to ensure normal distribution. Positive values indicate higher expression in psoriasis samples versus other skin diseases and vice versa for negative values.
AD, atopic dermatitis; CE, contact eczema; HC, healthy controls; LP, lichen planus; Pso, psoriasis vulgaris. n¼150.
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well as in CE. HLA-related genes, including HLA-DPa1, HLA-
DRA, and HLA-DFB1, were typically found in LP and CE,
whereas type I/III IFN-associated genes, including CXCL9,
ISG15, and Mx1/IFI78, were specifically found in LP, Pso, and
CE but not in AD and HC. These results are in accordance with
earlier studies concerning gene markers in these other inflam-
matory diseases and support the informative value of our
approach (Pedersen et al., 2007; Wenzel et al., 2008;
Kamsteeg et al., 2010).
IL-17/TNFa-associated genes are specifically expressed in
psoriasis skin samples
In psoriasis, the unsupervised cluster analysis revealed a large
set of mainly IL-17/TNFa-associated inflammatory genes speci-
fically expressed in this disease (detailed data are provided in
Supplementary 2 online). Interestingly, this cluster included a
number of genes regulated only by a combined effect of TNFa
and IL-17, including the inflammatory response genes S100A15
(Koebnerisin), S100A12, the platelet-derived growth factor
(PLAT), and the cytokines IL-19 and IL-36Ra. Further, genes
in this cluster were LCN2 (Lipocalin 2), which is regulated by
IL-17 alone, and the cytokine IL-36g, which may be induced by
IL-17 or TNFa alone, as well as by combined treatment with
TNFa and IL-17 (Chiricozzi et al., 2011).
SAM analyses identify potential discriminators between psoriasis
and other inflammatory skin disorders
In the next step, we performed a set of Significance Analysis of
Microarrays (SAM) (Tusher et al., 2001) comparing the gene
expression results in psoriasis with that of the other inflammatory
diseases (AD, LP, and CE) in order to identify potential markers
for psoriasis (Figure 1b and Supplementary Table 2 online).
These analyses revealed the upregulation of several specific
genes in the psoriasis samples, most of them in concordance
with the genes seen in the psoriasis-specific cluster achieved by
the unsupervised cluster analysis (Figure 1a), including IL-36g,
IL-36Ra, S100A15, LCN2, ATP12A, GJB6, TGM3, and CD24.
Volcano plot identifies IL-36c/IL-1F9 as a specific psoriasis
marker
To focus on single genes that might serve as specific psoriasis
biomarkers, we used a volcano plot to visualize the most
significantly and differentially expressed genes in psoriasis
versus the other inflammatory skin diseases (Figure 1c) (Chen
et al., 2007). This approach revealed IL-36g/IL-1F9 as the clear
top outlier, and therefore we selected this gene as the most
promising candidate for our subsequent analysis. Interestingly,
the expression of IL-36g was only moderately associated with
the expression of other potential psoriasis markers, including
S100-A7, -A8, -A9, -A15, DEFB4, and IL-19 (r¼ 0.43–0.64,
P¼0.018–0.001, see Supplementary 2 online).
Immunohistology confirms the strong expression of IL-36c in
psoriasis
To confirm the expression of IL-36g on the protein level,
we performed immunohistological analyses in the corres-
ponding skin samples. These analyses clearly reflected the
picture of IL-36g expression observed in the gene expression
analyses (Figure 2a). Psoriasis samples showed a strong expres-
sion of IL-36g in the upper epidermal layer, mostly in four and
more cell layers, whereas this staining was only weakly found
in the control diseases (AD, LP, and CE) and absent in HCs
(Figure 2b). As depicted in Figure 2c, the gene expression score
in these samples was closely associated with the histological
score (Spearman’s r¼0.71, Po0.01). In addition, we analyzed
the lesional IL-36g expression in pustular psoriasis, which was
similar to the Pso findings (Supplementary 3 online).
Low IL-36c protein expression in other erythrosquamous skin
disorders
In the next step, we included additional erythrosquamous skin
diseases with potential differential diagnoses to psoriasis
(pityriasis lichenoides, subacute cutaneous lupus erythemato-
sus, tinea, and mycosis fungoides, n¼5, respectively) in the
immunohistological analyses. In all these entities, only weak
Table 1. Top 10 expressed genes in inflammatory skin diseases versus healthy controls
AD LP Pso CE
Gene Count1 Gene Count Gene Count Gene Count
1 S100A8 4.64 S100A8 4.23 S100A8 6.37 S100A8 4.76
2 LCE3D 3.73 KRT16 3.35 S100A9 5.70 S100A9 3.87
3 S100A9 3.53 S100A9 3.17 DEFB4 5.01 S100A7 3.02
4 CCL18 3.45 CCL18 3.05 S100A7 4.68 CCL18 3.01
5 S100A7 3.17 IFI27 2.92 LCE3D 4.36 KRT16 2.87
6 KRT16 3.07 KRT6 2.86 KRT6 4.01 CCL17 2.66
7 KRT6 2.34 LCE3D 2.85 SPRR2 3.94 LCE3D 2.56
8 AKR1B10 2.19 CXCL9 2.75 KRT16 3.77 MMP12 2.55
9 IFI27 2.10 S100A7 2.63 AKR1B10 3.22 TNFC 2.46
10 SPRR1A/B 1.92 BST2 1.99 FABE 3.09 CCL19 2.25
Abbreviations: AD, atopic dermatitis; CE, contact eczema; LP, lichen planus; Pso, psoriasis vulgaris.
1Count: differential expression (based on a log2 score) of the specific gene in disease versus healthy control (Skin Patho PIQOR microarray, Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany).
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expression of IL-36g was observed (Supplementary Figure 2b
online).
IL-36c serum levels in peripheral blood are enhanced and
correlate with disease activity
IL-36g ELISA analyses of peripheral blood serum samples
(taken from psoriasis patients in different stages of disease, as
well as from healthy donors and patients who suffered from
AD) were performed to investigate a potential systemic
relevance of this cytokine. As depicted in Figure 3a, IL-36g
levels in untreated psoriasis patients were significantly ele-
vated when compared with AD and HC (Po0.01). Impor-
tantly, the IL-36g serum levels in all psoriasis patients (under
treatment and untreated) correlated closely to the disease
5.00 Strong
Fair
WeakH
is
to
 s
co
re
None
–1 0 1 2 3 4
Gene expression level
P<0.01
IL36γ gene expression
IL36γ histo score
P<0.01
4.00
3.00
2.00
1.00
0.00
–1.00
–2.00
Strong
Fair P<0.01
Weak
None
HC AD LP Pso CE PL SCLE Tinea MF
HC AD LP CEPso
=0.71
P<0.01
Figure 2. IL-36c gene and protein expression in psoriasis and other skin diseases. (a) Individual gene expression score of IL-36g in psoriasis skin lesions and
controls (n¼ 30 for each subset). Comparison of IL-36g gene expression in psoriasis versus HC, AD, LP, and CE: each comparison significant with Po0.01 (Mann–
Whitney U-test). (b) Protein expression of IL-36g in different erythrosquamous skin diseases (mean expression±SEM; Po0.01, Mann–Whitney U-test) and
corresponding representative immunohistological micrographs (original magnification  200, scale bar¼0.1mm). n¼10 for HC, AD, LP, Pso, and CE,
respectively, and n¼ 5 for PL, SCLE, Tinea, and MF, respectively. (c) Correlation (Spearman’s r) between gene expression and histological score. Included are 40
of the original samples, with n¼ 10 for HC, AD, LP, and Pso, respectively. HC, healthy controls; AD, atopic dermatitis; LP, lichen planus; Pso, psoriasis vulgaris;
CE, contact eczema; PL, pityriasis lichenoides; SCLE, subacute cutaneous lupus erythematosus; MF, mycosis fungoides.
Table 2. Potential discriminators of psoriasis versus other inflammatory skin disorders
Pso versus AD Pso versus LP Pso versus CE Pso versus HC
Up Pso Up AD Up Pso Up LP Up Pso Up CE Up Pso Up HC
Gene Rate1 Gene Rate Gene Rate Gene Rate Gene Rate Gene Rate Gene Rate Gene Rate
1 IL-36g 10.2 CCL18 7.3 S100A15 11.2 HLA-DPB1 7.1 IL-36g 9.2 CD52 7.1 S100A8 28.3 IL-37 9.7
2 DEFB4 9.7 CRIP1 7.0 SPRR2 10.0 CD52 6.8 S100A15 8.0 CRIP1 6.2 S100A9 25.2 SERPINA12 9.2
3 S100A15 8.4 CCL27 7.0 DEFB4 9.7 CCL18 6.7 GJB6 7.4 CCL27 6.0 S100A7 23.0 CST6 9.0
4 LCN2 8.0 CCL17 5.3 LCN2 9.4 MMP9 6.1 DEFB4 7.2 CCL18 5.9 SPRR2 18.3 CCND1 8.9
5 GJB6 7.8 ALCAM 4.9 IL-36g 9.3 HLA-DPA1 6.1 FABE 7.1 CCL17 5.7 FABE 17.1 — —
6 CRABP2 6.8 LGALS1 4.8 S100A9 8.4 RARRES3 6.0 IL-36Ra 6.4 KAP10 5.4 LCE3D 17.0 — —
7 IL-36Ra 6.7 CCL13 4.7 ATP12A 8.0 CXCL9 5.9 SPRR2 6.1 TNFC 5.3 KRT16 14.9 — —
8 FABE 6.7 MS4A6A 4.6 TGM3 7.5 TNFC 5.8 ARG 6.0 TIMP1 5.2 KRT6 14.7 — —
9 SPRR2 6.5 PRRX1 4.5 MGC70195 7.4 KAP10 5.8 CD24 6.0 CORO1A 5.0 AKR1B10 14.3 — —
10 ATP12A 6.5 POSTN 4.4 CD24 7.3 CRIP1 5.7 HBP17 5.8 ALCAM 5.0 IFI27 13.8 — —
Abbreviations: AD, atopic dermatitis; CE, contact eczema; HC, healthy controls; LP, lichen planus; Pso, psoriasis vulgaris; Up, upregulation.
1Rate: the observed relative expression rate as calculated by SAM analyses.
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activity as determined by psoriasis area and severity index
(depicted in Figure 3b, Spearman’s r¼0.91, Po0.01).
Significant decrease in IL-36c serum levels under anti-TNFa
treatment
To investigate the impact of an anti-inflammatory drug on the
IL-36g serum levels, serum samples of seven psoriasis patients
before (‘‘baseline’’) and after 24-week (‘‘under treatment’’)
treatment with the anti-TNFa drug etanercept were analyzed.
Here the anti-TNF-treatment led to a significant decline of the
IL-36g serum levels (see Figure 3c). Detailed data are provided
in Supplementary 4 online.
Predictive diagnostic value of IL-36c staining in skin biopsies
Finally, we investigated the predictive diagnostic value
of immunohistological IL-36g staining as a diagnostic
marker in unclear cases. We identified 21 samples in our
database with a clinical follow up of at least 2 years, which
had been difficult to classify in the primary histological
biopsy (taken between 2009 and 2011) but were diagnosed
either ‘‘psoriasis’’ or ‘‘eczema’’ in the meantime. These
biopsies were stained for IL-36g expression, blinded, and
evaluated by two experienced dermatopathologists (AD and
JW). A strong expression of IL-36g (X4 cell layers) was
specifically found in psoriasis (n¼7), whereas low expression
(p1 cell layer) was only found in eczema (n¼ 8). Six
cases showed a marginal IL-36g expression (2–3 cell layers)
and could not be reliably classified based on their IL-36g
staining.
Beyond the threshold values (X4 andp1, respectively), the
staining was entirely consistent with the clinical diagnosis––
i.e., in 15 out of 21 samples, we were able to assign a specific
diagnosis based solely on IL-36g staining. Twenty-nine percent
of the cases remained unclassified (Figure 3d). Using the given
critical value (X4), IL-36g had a highly specific positive
predictive diagnostic value for psoriasis.
DISCUSSION
In the present study, gene expression analyses in patients with
different inflammatory skin diseases revealed a cluster of genes
significantly upregulated in psoriasis, which are particularly
regulated by IL-17 and TNFa (Chiricozzi et al., 2011). Among
these, IL-36g was found to be the most specifically regulated
gene in psoriasis when compared with other inflammatory
skin diseases. This finding was confirmed by immunohisto-
chemistry (IHC) on the protein level. Importantly, IL-36g blood
serum levels were closely associated with the psoriasis disease
activity (as measured by psoriasis area and severity index) and
decreased under treatment with anti-TNFa drugs, and IL-36g
IHC was useful in tissue diagnosis of psoriasis from eczema.
Biological function of IL-36c
IL-36g belongs to the newly identified IL-36 cytokine family,
formerly known as IL-1F cytokines, which is related to the IL-1
family. The IL-36 family comprises the agonistic cytokines
IL-36a (¼ IL-1F6, also called IL-1e), IL-36b (¼ IL-1F8), and
IL-36g (¼ IL-1F9), as well as the antagonistic cytokine IL-36Ra
(¼ IL-1F5, also called IL-36RN and IL-1d) (Dinarello et al.,
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Figure 3. IL-36c peripheral blood serum levels and predictive value of IL-36c immunohistochemistry. (a) Mean IL-36g blood serum levels±SEM in untreated
patients with psoriasis (Pso, n¼ 7), atopic dermatitis (AD, n¼ 5), and healthy controls (HCs, n¼ 7). (b) Correlation (Spearman’s r) between PASI (psoriasis area and
severity index) score and IL-36g serum levels in treated and untreated individuals (Psountreated n¼7, Psotreated n¼7, and HCs, n¼ 7). (c) Individual and mean IL-
36g serum levels in untreated (baseline) and etanercept-treated (after 24 weeks of treatment) psoriasis patients. Wilcoxon signed-rank test. (d) Representative
micrographs of psoriasis and eczema skin biopsies (hematoxylin and eosin staining, IL-36g immunohistochemistry, original magnification  200, scale
bar¼ 0.1 mm); table of predictive value of IL-36g immunohistochemistry (divided into three categories depending on the amount of cell layers stained: X4/2–3/
p1 cell layers; n¼ 21). Pso, psoriasis vulgaris.
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2010). Recent evidence indicates that the IL-36 cytokines
activate similar intracellular signals as IL-1 and are involved in
the regulation of innate, as well as adaptive immune responses
(Vigne et al., 2011). The agonistic IL-36R ligands stimulate
pro-inflammatory pathways by binding to IL-1 receptor-like 2
(IL-1RL2) and IL-1RAcP resulting in the activation of mitogen-
activated protein kinase and NF-kB signal transduction. They
signal through the mitogen-activated protein kinase, c-Jun
N-terminal kinase, and extracellular signal–regulated kinase1/
2 pathways and enhance the secretion of pro-inflammatory
factors including IL-6 and IL-8 (Towne et al., 2004; Boraschi
and Tagliabue, 2013).
The IL-36s are expressed in a restricted manner, primarily
by keratinocytes in the skin but also by other epithelial tissue
including bronchial epithelia, suggesting that these proteins
are involved in first-line defenses against microorganisms
(Gresnigt and van de Veerdonk, 2013). Interestingly, IL-36
cytokines also have synergistic effects on the induction of
antimicrobial peptides by IL-17A or TNFa, indicating that
Th17 cytokines and IL-36 can reinforce similar responses in
keratinocytes (Carrier et al., 2011).
IL-36g expression is upregulated by toll-like receptor ligands
including polyinosinic-polycytidylic acid (poly(I:C)) and fla-
gellin, supporting the notion that IL-36g might act as an
alarmin and is expressed in response to activation of the innate
immune system (Lian et al., 2012). IL-36g induces the
production of several pro-inflammatory cytokines, including
IL-12, IL-6, TNFa, and IL-23, and contributes to skin
inflammation by acting on keratinocytes, dendritic cells,
and, indirectly, on T lymphocytes (Vigne et al., 2011; Foster
et al., 2014). Vice versa, IL-17 and TNFa, which both are
typically expressed by immune cells, are able to enhance the
expression of IL-36g by keratinocytes (Chiricozzi et al., 2011;
Johnston et al., 2013). Therefore, IL-36g appears to have a
central amplifying position in pro-inflammatory pathways at
the interface between innate and adaptive immunity (Vigne
et al., 2011; Lowes et al., 2013).
Role of IL-36c in inflammatory skin diseases
The first evidence for a potential role of the IL-36 family in
inflammatory skin diseases emerged in 2007 when Blumberg
et al. (2007) generated transgenic mice expressing IL-36a/IL-
1F6 in basal keratinocytes. These mice developed a psoriasis-
like skin phenotype characterized by acanthosis, hyper-
keratosis, and the presence of a mixed inflammatory cell
infiltrate. In addition, the authors found an increased
expression of IL-36a in human psoriatic skin. These findings
were supported by two subsequent studies: Johnston et al.
(2011) found an increased expression of all IL-36 cytokines (a,
b, and g) and of IL-36Ra in human psoriasis skin lesions
(n¼ 20), as well as in two psoriasis mouse models (KC-Tie2
mice and imiquimod-treated C57BL/6 mice) by PCR and IHC.
He et al. (2013) showed an enhanced expression of IL-36g in
human psoriasis skin lesions.
These results are confirmed by our own findings, revealing
IL-36g as a highly expressed marker within psoriasis skin
lesions. Unlike other markers described earlier in psoriasis,
including, for example, the S100 proteins A7, A8, and A9
(Semprini et al., 1999; Liu et al., 2007; Glaser et al., 2009;
Kerkhoff et al., 2012), IL-36g was highly specific for psoriatic
inflammation but only weakly expressed in other inflammatory
skin diseases (AD, CE, and LP). These data are in accordance
with the results by Kamsteeg et al. (2010), who found a high
expression of IL-36g in psoriasis but not in eczematous diseases.
In addition to these findings, our IHC results demonstrate the
potential impact of this marker in the discrimination of psoriasis
against other most common erythrosquamous skin diseases,
including also pityriasis lichenoides, subacute cutaneous lupus
erythematosus, tinea, and mycosis fungoides.
Recent studies implicate a central role for the IL-36s in the
pro-inflammatory network in psoriasis. Overexpression of IL-
36 in mouse skin leads to a disease quite similar to human
plaque psoriasis, and inhibition of IL-36 in human psoriatic
skin ameliorates the inflammation (Towne and Sims, 2012).
This psoriasis-like dermatitis in mice is driven by IL-36-
mediated DC keratinocyte cross talk (Tortola et al., 2012).
Human keratinocytes derived from patients with psoriasis
have been shown to express significantly higher levels of IL-
36g in response to IL-17 compared with those isolated from
healthy donors (Muhr et al., 2011). Vice versa, aberrant
function of the IL-36Ra (¼ IL-36RN) results in an
unregulated secretion of pro-inflammatory cytokines and the
clinical picture of a severe psoriasis with pustular lesions
(Marrakchi et al., 2011; Onoufriadis et al., 2011). These
findings make the IL-36 system a promising drug target in
psoriasis. This is supported by the recent development of an
anti-IL-36-receptor antibody (WO2013074569) for clinical
use in psoriasis (Wolf and Ferris, 2014).
IL-36c as a potential biomarker in psoriasis
Our data demonstrate that IL-36g is not only a specific
psoriasis marker for skin lesions but that IL-36g peripheral
blood serum levels are closely correlated with the disease
activity and clearly decrease under treatment with the anti-
TNFa drug etanercept. These latter findings are supported by
Johnston et al. (2011) who detected a decrease in lesional
expression of IL-36g mRNA in the skin under treatment with
this drug. Furthermore, we demonstrated that IL-36g might be
a helpful diagnostic marker in the at times difficult histological
differential diagnosis between eczematous psoriasis and
psoriasiform eczema. Here strong expression of IL-36g (X4
cell layers) in IHC was found to be a highly specific diagnostic
marker for psoriasis.
Conclusion
Our results demonstrate that psoriasis skin lesions are char-
acterized by the expression of a specific gene cluster, includ-
ing several IL-17/TNFa-associated cytokines. Among these,
IL-36g is the most outstanding marker. IL-36g expression in
psoriasis skin lesions is significantly enhanced when com-
pared with other erythrosquamous skin diseases. IL-36g
peripheral blood serum levels are closely associated with
disease activity (psoriasis area and severity index) and decline
under anti-TNFa treatment. Finally, IL-36g IHC has a highly
positive predictive value to discriminate psoriasis from
eczema skin lesions in unclear cases.
AM D’Erme et al.
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These features highlight IL-36g as a valuable future biomar-
ker in psoriasis patients, both for diagnostic purposes and for
monitoring of disease activity during the clinical course.
Furthermore, IL-36g might also provide a future drug target,
because of its potential amplifier role in TNFa and IL-17
pathways in psoriatic skin inflammation.
MATERIALS AND METHODS
Skin samples
Skin samples of 150 donors (30 patients with Pso, AD, CE, LP, and
HC, respectively) were analyzed. Only biopsies taken from untreated
patients with typical skin lesions were included. Diagnosis was
confirmed by standard histological techniques in every case. The
study was approved by the local ethic committee in Bonn (No.
12201) and fulfils the Declaration of Helsinki Principles. All patients
signed a consent form. Skin samples were divided into two parts
immediately after excision. One part was flash frozen in liquid
nitrogen and later processed for mRNA isolation. The second part
was fixed in 5% formalin solution over night and was subjected to
conventional histological investigation and IHC. The details of this
study have been described before (Wenzel et al., 2008). In addition,
skin samples of other erythrosquamous skin diseases (pityriasis
lichenoides, n¼ 5), subacute cutaneous lupus erythematosus (n¼ 5),
Tinea (n¼ 5), mycosis fungoides (n¼ 5), and previously unclassified
psoriasiform dermatitis (n¼ 21) were included from the authors
archives.
RNA isolation
Isolation of total RNA from skin excision biopsies was performed
using TriReagent (Sigma, St Louis, MO) and the NucleoSpin 96
RNAKit (Macherey and Nagel, Dueren, Germany). RNA was quanti-
fied by photometrical measurement, and the integrity was assessed
using a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Gene expression analyses
The Skin Patho PIQOR (Parallel Identification and Quantification of
RNAs) microarray (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) was used for gene expression analyses. Here Cy5-labeled
RNA from disease samples was hybridized against a Cy3-labeled
common skin reference pool, as described before (Wenzel et al.,
2008). Hybridization, scanning, and data analysis were performed in
accordance with the MIAME (Minimum information about a
microarray experiment) standards. All raw data are available at
GEO (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/),
accession number GSE63741.
Histology and immunohistology
Sections were prepared from formalin-fixed, paraffin-embedded skin
biopsies. Standard hematoxylin and eosin, as well as periodic acid
Schiff staining were performed for diagnostic purposes. The protein
expression of IL-36g was analyzed by IHC using the monoclonal
mouse IgG1 anti-human-IL-36g antibody ab156783 (Abcam Inc.,
Cambridge, MA) without pretreatment with a dilution of 1:500. The
lesional IL-36g expression was scored semiquantitatively (0¼ no
expression; 1¼weak expression; 2¼ fair expression and 3¼ strong
expression) by two experienced dermatopathologists (JW and AD)
(Wenzel et al., 2005). Visualization was performed using the REAL
staining kit (DAKO, Hamburg, Germany) with Fast Red as chromogen.
IL-36c blood serum concentrations
Blood samples of patients with psoriasis in stage of untreated active
disease (‘‘baseline’’), as well as after 24 weeks of systemic treatment
with etanercept (‘‘24-week treatment’’) (at the dose of 50 mg twice a
week for 12 weeks followed by 50 mg once a week) were collected in
our outpatient clinic (Pso untreated: n¼ 7, Pso treated: n¼ 7). In
addition, the psoriasis area and severity index score was determined
for each patient to measure the disease activity at the different time
points. Furthermore, serum samples from untreated AD patients
(n¼ 5) and healthy donors (HCs, n¼ 7) were taken for control
purposes. Serum samples were obtained from peripheral blood,
centrifuged at 1,500g at 4 1C for 15 minutes, and subsequently stored
at  20 1C until analysis. The serum concentrations of IL-36g
were measured in duplicates by ELISA using a commercial kit
(SEL621Mu, Cloud-Clone, Houston, Tx) according to the manufac-
turer’s protocol.
Statistical analysis
Gene expression analyses. Primary statistical analyses were
performed by using the TMEV software, version 4.9 (Dana-Farber
Cancer Institute, Boston, MA). Unsupervised hierarchical cluster
analysis with Pearson’s correlation coefficient was used to investi-
gate the average linkage of the genes within the different subsets
(Eisen et al., 1998). To identify potential marker genes in psoriasis,
Significance Analysis for Microarrays was used to identify genes
specifically expressed in the different subsets (expression42-fold
enhanced, Po0.01) (Tusher et al., 2001). This method included
two-sided unpaired t-tests for each of the 1,539 unique genes
represented on the microarray chip using the R programing
environment and the Bioconductor platform. Raw P-values were
corrected for multiple testing by the Bonferroni method (Tusher
et al., 2001). Subsequently, a volcano plot was created as a widely
used approach to visualize the significance of differentially
expressed genes in microarray analysis (Chen et al., 2007).
Corrected P-values are represented on the y-axis of the
volcano plot after a negative log10 transformation as a common
standard. Gene expression values were log2 transformed to ensure
normal distribution of the data as a prerequisite for the subsequent
statistical methods according to standard procedures in microarray
analysis.
Statistics for IHC and ELISA analysis. Using SPSS 22, the non-
parametrical Mann–Whitney U-test was performed to compare
the mean staining intensity of IL-36g in the different skin diseases,
as well as to compare mean serum levels as determined by ELISA.
The Wilcoxon signed-rank test was used to compare IL-36g serum
levels before and after Etanercept treatment. Correlation analyses
were performed by calculating Spearman’s rho. P-level o0.05
was considered to be significant (*) and P-level o0.01 as highly
significant (**).
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